Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 7, 2016
Pharmacy Choice - News - U.S. Pharmaceutical Industry - February 7, 2016

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/6/16 - Japan : Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer Antibody-Drug Conjugates and XMT-1522 [TendersInfo (India)]
Mersana Therapeutics and Takeda Pharmaceutical Company Limited today announced that they have entered a new strategic partnership granting Takeda rights to Mersanas lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to
2/6/16 - Patent Issued for Compositions, Synthesis, and Methods of Using Phenylcycloalkylmethylamine Derivatives (USPTO 9238625)
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week REVIVA PHARMACEUTICALS, INC. has been issued patent number 9238625, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventors are Bhat, Laxminarayan; Adiey, Kouacou; Bhat, Seema Rani. This patent was filed on December 31, 2
2/6/16 - Researchers Submit Patent Application, "Methods and Agents for Preventing and Treating Plasma Cell Dyscrasias", for Approval (USPTO 20160008307)
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week From Washington, D.C., NewsRx journalists report that a patent application by the inventors Orlow, Seth J.; Mazumder, Amitabha; Doudican, Nicole, filed on February 25, 2014, was made available online on January 21, 2016. No assignee for this patent application has been made.
2/5/16 - "Pharmaceutical Composition of Doxycycline with Reduced Food Effect" in Patent Application Approval Process (USPTO 20160008379)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors JAMI, Dileep; SINGH, Ravinder; FANDA, Anuj Kumar; SINGH, Romi Barat, filed on August 7, 2015, was made available online on January 21, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has no
2/5/16 - Pharma bro Martin Shkreli keeps mum at House hearing, calls Congress imbeciles [Yerepouni Daily News (Lebanon)]
Pharmaceutical CEO Martin Shkreli the "most hated man in America," who raised the price of an HIV treatment 5,500 percent remained silent during a congressional hearing on prescription drug prices. Summoned before the House Oversight and Government Reform Committee to give testimony on his former company's recent increases in prices of prescr
2/5/16 - Acasti Announces Share-for-Debt
Acasti Pharma Inc., an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces the issuance of fifty thousand class A common shares as part of a settlement agreement executed on February 5, 2016.
2/5/16 - Aclaris Therapeutics to Present at the 2016 Leerink Partners Annual Global Healthcare Conference
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, today announced that Dr. Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology.
2/5/16 - Aegerion Pharmaceuticals Announces Presentation at the Leerink Partners Global Healthcare Conference [Arab News (Saudi Arabia)]
-Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the Leerink Partners 5th Annual Global Healthcare Conference in New York City. Chief Executive Officer Mary Szela..
2/5/16 - Affinivax Secures Additional Funding to Advance its Novel Pneumococcal Vaccine towards Clinical Trials
Affinivax Inc., a biotechnology company dedicated to developing novel vaccines, today announced receipt of a $2.5 million investment from the Bill& Melinda Gates Foundation. This additional investment from the Gates Foundation validates the excellent progress we have made since we founded the company last year, said Steven B. Brugger, CEO of
2/5/16 - Agile Therapeutics, Inc. Announces Full Exercise of Option to Purchase Additional Shares by Underwriters [Jerusalem Post (Israel)]
-Agile Therapeutics, Inc., a womens health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 826,771 shares of...
2/5/16 - Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE dalbavancin
By a News Reporter-Staff News Editor at Drug Week Allergan plc, a leading global pharmaceutical company, announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application to update the label for DALVANCE for injection. "Hospitals are facing pressures to reduce hospitalizations and readmissions, while...
2/5/16 - Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
Amarantus BioScience Holdings, Inc., a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation from the US Food and Drug Administration for treating retinitis pigmentosa with MANF. MANF was previously granted orphan drug...
2/5/16 - Big Pharma's worst nightmare
On a hot August afternoon in 2000, four Americans arrived for a secret meeting at the central London penthouse flat of an Indian billionaire drug manufacturer named Yusuf Hamied. A sixth person would join them there, a French employee of the World Health Organisation, who was flying in from Geneva, having told his colleagues he was taking leave.
2/5/16 - Biota Pharmaceuticals Reports Second Quarter Fiscal Year 2016 Financial Results
Biota Pharmaceuticals, Inc. today announced its financial results for the three month period ended December 31, 2015, which is the second quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate developments.. I am very pleased today to report that significant progress is being made with our antiviral pipeline
2/5/16 - Blueprint Medicines Appoints Lonnel Coats to Board of Directors [Global Data Point]
Prior to joining Lexicon in July 2014, Mr. Coats served in a series of leadership positions at Eisai Inc. and Eisai Corporation of North America, U.S. subsidiaries of Tokyo- based Eisai Co., Ltd., from 1996 through June 2014, including as chief executive officer of Eisai Inc. from 2010 to June 2014.&# x0D;. In this role, Mr. Coats helped establish
2/5/16 - Boehringer Ingelheim - SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
Release date- 04022016- Ingelheim, Germany,- Boehringer Ingelheim today announced that SPIRIVA RESPIMAT is now available for the treatment of asthma by prescription in U.S. pharmacies. 'Despite taking other daily maintenance treatments, many people with asthma continue to experience symptoms, including coughing, wheezing, shortness of breath,' said
2/5/16 - Califf, FDA top officials call for sweeping review of agency opioids policies [Global Data Point]
As one of the cornerstones of this plan, the FDA will seek guidance from outside experts in the fields of pain management and drug abuse. For example, the FDA has already asked the National Academy of Medicine to help develop a framework for opioid review, approval and monitoring that balances individual need for pain control with considerations of
2/5/16 - Canada Pharmaceutical Industry Report 2016
Dublin- Research and Markets has announced the addition of the "Canada Pharmaceutical Industry 2016" report to their offering. Canada also has the fourth fastest growing pharmaceutical industry after China, the US and Spain and has shown a steady growth trend. The pharmaceutical industry is one of the most innovative and profitable industries in Ca
2/5/16 - Canada Pharmaceutical Industry Report 2016 - Research and Markets
Research and Markets has announced the addition of the " Canada Pharmaceutical Industry 2016" report to their offering. Canada also has the fourth fastest growing pharmaceutical industry after China, the US and Spain and has shown a steady growth trend. The pharmaceutical industry is one of the most innovative and profitable industries in Canada.
2/5/16 - Catalyst Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference [Jerusalem Post (Israel)]
-Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Patrick J. McEnany, Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/Chief Operating Officer will present at the 18th Annual BIO CEO&..
2/5/16 - Collegium Announces Issuance of U.S. Patent Covering DETERx, an Abuse-Deterrent, Extended-Release Technology Platform [Emirates News Agency (WAM) (United Arab Emirates)]
-Collegium Pharmaceutical, Inc. today announced that U.S. Patent No. 9,248,195 entitled, "Abuse-deterrent Pharmaceutical Compositions of Opioids and Other Drugs" was issued by the U.S. Patent and Trademark Office. This is the eighth issued U.S. patent related to the DETERx technology platform. We have a number of additional patent applications curr
2/5/16 - CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) to Ring The Nasdaq Stock Market Closing Bell
What: CoLucid Pharmaceuticals, Inc., a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, will visit the Nasdaq MarketSite in Times Square. Where: Nasdaq MarketSite 4 Times Square 43 rd& Broadway Broadcast Studio. Gal 3 C/06C 95.05 degre
2/5/16 - Concert Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Feb. 5 Concert Pharmaceuticals, Lexington, Massachusetts, has been assigned a patent developed by Roger D. Tung, Lexington, Massachusetts, for deuterated rigosertib. The patent application was filed on April 19, 2013. Written by Kusum Sangma; edited by Jaya Anand.
2/5/16 - Concert Pharmaceuticals Assigned Patent for Deuterated Derivatives of Ruxolitinib
ALEXANDRIA, Va., Feb. 5 Concert Pharmaceuticals, Lexington, Massachusetts, has been assigned a patent developed by five co-inventors for "deuterated derivatives of ruxolitinib." The co-inventors are I. Robert Silverman, Arlington, Massachusetts, Julie F. Liu, Lexington, Massachusetts, Adam J. Morgan, Ashland, Massachusetts, Bhaumik Pandya, Arling
2/5/16 - CPhI announces findings from its review of the US pharma manufacturing market
Overall, the review demonstrates that US pharma industry and domestic manufacturers are showing increased confidence of renewed growth...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415